53. シェーグレン症候群
[臨床試験数:234,薬物数:270(DrugBank:85),標的遺伝子数:49,標的パスウェイ数:174]
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04563195 (ClinicalTrials.gov) | November 2020 | 12/9/2020 | BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome | BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Drug: tibulizumab (LY3090106) | Matthew C. Baker | NULL | Not yet recruiting | 18 Years | 85 Years | All | 12 | Phase 2;Phase 3 | United States |